Document is current

Article History

Received: 30 June 2023

Accepted: 25 October 2023

First Online: 20 November 2023

Declarations

:

: This study was approved by the University of Tasmania Research Ethics Review Committee (#26681). All participants involved in qualitative interviews provided informed consent prior to data collection commencing. Prior to data collection, interview participants were provided with a participant information outlining the aims and structure of the semi-structured interviews. The quantitative component of the evaluation analysed routine Quality Assurance data collected during standard clinical care at SHST. Therefore, no consent process was in place, and a waiver of consent was granted to analyse project data in accordance with Australian guidelines [42]. All methods were performed in accordance with the relevant guidelines and regulations.

: Not applicable.

: Joe Doyle’s institution has received investigator-initiated research funding from Gilead Science, AbbVie, Merck and Bristol Myers Squibb, and consultancy funding from Gilead, Abbvie, and Merck. Alisa Pedrana’s institution has received investigator-initiated research funding from Gilead Science, AbbVie, Merck has consultancy and speaker fees from Gilead. All other authors have no competing interest.